Search

Displaying results 5611 - 5620 of 10000 in total
  1. Drug

    Domiphen

    go.drugbank.com/drugs/DB11594
    Approved

    Domiphen bromide is a quaternary ammonium compound that is predominantly employed as a topically administered antiseptic agent.

  2. Drug

    Inhibitor of P38 Kinase

    go.drugbank.com/drugs/DB01953
    Experimental

    This compound belongs to the indoles. These are compounds containing an indole moiety, which consists of a pyrrole ring fused to benzene to form 2,3-benzopyrrole. … This drug is known to target mitogen-activated protein kinase 14.

  3. Drug

    Telazorlimab

    go.drugbank.com/drugs/DB16374
    Investigational

    Telazorlimab is under investigation in clinical trial NCT03568162 (Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis).

  4. Drug

    Pegmusirudin

    go.drugbank.com/drugs/DB19220
    Investigational

    Pegmusirudin is under investigation in clinical trial NCT00074620 (A Clinical Study to Assess the Safety of Peg-hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis).

  5. Drug

    Bevirimat

    go.drugbank.com/drugs/DB06581
    Investigational

    This compound belongs to the androgens and derivatives, which are hydroxylated C19 steroid hormones. They are known to favour the development of masculine characteristics. … It is not currently FDA-approved, but is undergoing clinical trials conducted by the pharmaceutical company Panacos.

  6. Drug

    Alferminogene tadenovec

    go.drugbank.com/drugs/DB05306
    Investigational

    Alferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease … Alferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration from a standard

  7. Drug

    Icotinib

    go.drugbank.com/drugs/DB11737
    Investigational

    . was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). … Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc

    Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
  8. Drug

    Moxazocine

    go.drugbank.com/drugs/DB20517
    Experimental

    The usage of the INN stem '-azocine' in the name indicates that Moxazocine is a narcotic antagonist/agonist related to 6,7-benzomorphan. Moxazocine has a monoisotopic molecular weight of 287.19 Da.

  9. Drug

    CRx-139

    go.drugbank.com/drugs/DB05744
    Experimental

    The synergistic combination containing low doses of the glucocorticoid steroid prednisolone and the antidepressant paroxetine. … It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects.

  10. Drug

    NTLA-2002

    go.drugbank.com/drugs/DB17597
    Investigational

    It is an investigational therapy designed to knock out the target gene kallikrein B1 (KLKB1) to reduce plasma kallikrein activity, thereby preventing hereditary angioedema attacks.[L45738] … NTLA-2002 is a lipid nanoparticle encapsulating single guide RNA (G012267) targeting the human KLKB1 gene and messenger RNA (mRNA000042) encoding Cas9.

    Synonyms: lipid nanoparticle encapsulating single guide RNA (G012267) targeting the human KLKB1 gene and messenger RNA (mRNA000042) encoding Cas9